NAGE
Niagen Bioscience, Inc.
$3.37
-0.08 (-2.32%)
At close · Jul 8
Market Cap
$268.40M
Shares
79,644,327
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$3.37
Open$3.43
Day$3.33–3.51
52W$3.18–12.56
Avg vol 30d749K
Short int4.5M · 5.6% float · 6.9d
Short vol36%
Last earningsMay 6, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 6
Equibles Rating
blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 16.9 · calm
Equity put/call 0.86
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−40%
below
Price vs 50-day avg
−11%
below
RSI (14)
44
neutral
MACD trend
Positive
52-week position
2%
near low
Momentum
relative strength
1-month return
0%
trailing
6-month return
−48%
trailing
YTD return
−47%
this year
Relative strength
−56%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $4 › 200d $6 — 200d above 50d
Institutional flow
Accumulating
4 of 145 funds reported for Jun 30 · net +2.3K sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
5.65% of float · ▼ -4.6% MoM · 6.9 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
145 holders — mid 3-yr range
Squeeze score
68
elevated · 0–100
Fundamentals
Revenue growth
+30%
Y/Y
Gross margin
64%
expanding
EPS growth
+82%
Y/Y
Free cash flow
$12.8M
Valuation
P/E 16.1
in line
Balance sheet
$39.5M
net cash
Quant / Vol
risk profile
Volatility
49%
annualized · 1-yr
Max drawdown
−74%
past year
ATR
4.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Up next
Next earnings call
Aug 5, 2026
Est · unconfirmed
· in 4 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 6, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Guidance & track record
Latest guidance
· from the 8-K filed May 6, 2026
Net sales
· full year 2026
Initiated
10% – 15%
General & administrative
· full year 2026
Initiated
$3M – $4M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−40%
Bearish
Price vs 50-day avg
−11%
Bearish
RSI (14)
44
Neutral
MACD trend
Positive
Bullish
52-week position
2%
Bearish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $4 › 200d $6 — 200d above 50d
Institutional flow
Accumulating
4 of 145 funds reported for Jun 30 · net +2.3K sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
5.65% of float · ▼ -4.6% MoM · 6.9 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
145 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $3
Now $3 · 2%
52-wk high $13
vs 200-day avg -40%
vs 50-day avg -11%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $3.8M | Q1 2026 | — |
|
|
|||
| e-commerce revenue | $19.2M | Q1 FY2026 call | — |
| food-grade Niagen sales | $7.3M | Q1 FY2026 call | — |
| Niagen ingredient revenue | $8.2M | Q1 FY2026 call | — |
| True Niagen revenue | $22.4M | Q1 FY2026 call | — |
| Operating cash flow | $13.5M | Full Year 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NAGE
this stock
Niagen Bioscience, Inc.
|
$268.40M | -47.0% | +29.9% | 16.1 | 5.6% |
|
ONC
BeOne Medicines Ltd.
|
$436.30B | -0.6% | +22179.2% | 887.9 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$126.50B | +9.9% | +46.2% | 29.6 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.50B | -14.0% | +20.8% | 16.2 | 3.2% |
|
ARGX
Argenx SE
|
$57.20B | +8.8% | — | — | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NAGE | +5.6% | +0.0% | -48.2% | +5.6% | -47.0% |
| SPY | -0.2% | +0.8% | +7.4% | -0.2% | +9.3% |
| vs SPY | +5.8% | -0.8% | -55.6% | +5.8% | -56.3% |